SCHEMBL4160267

SCHEMBL4160267

Cc1ccc2c(c1)C1(NC(=O)NC1=O)C(=O)N2CC1CCCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 5/20 0.43
BRD4 O60885 2/20 0.40
POLB P06746 4/20 0.38
DRD4 P21917 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OPRL1 P41146 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179015 0.88 AKR1B1 (0.43) SCN9ACYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL4176531 0.85 SCN9A (0.50) SCN9APOLBCYP1A2CYP2C9CYP2C19
SCHEMBL4169761 0.84 OPRL1 (0.48) SCN9APOLBKMT2AOPRM1OPRD1
SCHEMBL4168465 0.83 OPRL1 (0.44) SCN9APOLBOPRM1OPRD1OPRK1
SCHEMBL4177865 0.83 OPRL1 (0.41) SCN9APOLBKMT2AALDH1A1KDM4E
SCHEMBL4165983 0.74 MAPT (0.44) POLBCYP2C9ALDH1A1MAPTHTT
SCHEMBL4261411 0.74 AKR1B1 (0.38) POLBCYP2C9KMT2AALDH1A1MAPT
SCHEMBL4255794 0.74 AKR1B1 (0.46) POLBKMT2AALDH1A1KDM4EMAPT
SCHEMBL4174404 0.73 AKR1B1 (0.39) POLBCYP2C9KMT2AALDH1A1KDM4E
SCHEMBL4255698 0.73 POLB (0.55) POLBKMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US claimed
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 SCN9A 176/4885BRD4 1098/4885POLB 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.